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Abstract
B lymphocytes are an important cell population of the immune system. However, until recently it was not possible to
transduce resting B lymphocytes with retro- or lentiviral vectors, making them unsusceptible for genetic manipulations by
these vectors. Lately, we demonstrated that lentiviral vectors pseudotyped with modified measles virus (MV) glycoproteins
hemagglutinin, responsible for receptor recognition, and fusion protein were able to overcome this transduction block.
They use either the natural MV receptors, CD46 and signaling lymphocyte activation molecule (SLAM), for cell entry (MV-LV)
or the vector particles were further modified to selectively enter via the CD20 molecule, which is exclusively expressed on B
lymphocytes (CD20-LV). It has been shown previously that transduction by MV-LV does not induce B lymphocyte activation.
However, if this is also true for CD20-LV is still unknown. Here, we generated a vector specific for another B lymphocyte
marker, CD19, and compared its ability to transduce resting B lymphocytes with CD20-LV. The vector (CD19ds-LV) was able
to stably transduce unstimulated B lymphocytes, albeit with a reduced efficiency of about 10% compared to CD20-LV,
which transduced about 30% of the cells. Since CD20 as well as CD19 are closely linked to the B lymphocyte activation
pathway, we investigated if engagement of CD20 or CD19 molecules by the vector particles induces activating stimuli in
resting B lymphocytes. Although, activation of B lymphocytes often involves calcium influx, we did not detect elevated
calcium levels. However, the activation marker CD71 was substantially up-regulated upon CD20-LV transduction and most
importantly, B lymphocytes transduced with CD20-LV or CD19ds-LV entered the G1b phase of cell cycle, whereas
untransduced or MV-LV transduced B lymphocytes remained in G0. Hence, CD20 and CD19 targeting vectors induce
activating stimuli in resting B lymphocytes, which most likely renders them susceptible for lentiviral vector transduction.
Citation: Kneissl S, Zhou Q, Schwenkert M, Cosset F-L, Verhoeyen E, et al. (2013) CD19 and CD20 Targeted Vectors Induce Minimal Activation of Resting B
Lymphocytes. PLoS ONE 8(11): e79047. doi:10.1371/journal.pone.0079047
Editor: Evren Alici, Karolinska Institutet, Sweden
Received April 15, 2013; Accepted September 18, 2013; Published November 11, 2013
Copyright:  2013 Kneissl et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grant 031A024C of the Federal Ministry for Education and Research of Germany as part of the Ci3 Cluster and by the
LOEWE Center for Cell and Gene Therapy Frankfurt funded by Hessisches Ministerium fu ¨r Wissenschaft und Kunst (III L 4-518/17.004 [2010]) to CJB. QZ was
supported by the China Scholarship Council and is an associated member of the DFG Graduiertenkolleg GRK1172. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: SK and CJB are listed as inventors in an international Patent Cooperation Treaty/European patent application (PCT/EP2007/008384
‘‘Pseudotyping of retroviral vectors, methods for production and use thereof for targeted gene transfer and high-throughput screening’’) assigned to the Paul-
Ehrlich-Institut, which includes as claims the generation of targeted lentiviral vectors. This does not alter the authors’ adherence to all the PLOS ONE policies on
sharing data and materials.
* E-mail: Christian.Buchholz@pei.de
¤ Current address: AbD Serotec, A Bio-Rad Company, Puchheim, Germany
. These authors contributed equally to this work.
Introduction
Playing a major role in the humoral immune response B
lymphocytes are responsible for antibody production, perform the
role of antigen-presenting cells (APCs) and eventually mature into
memory B lymphocytes after activation via antigen binding. These
properties make B lymphocytes important target cells for
immunotherapy approaches [1] and to investigate basic questions
in B lymphocyte related immunology. Furthermore, they are
target cells in many lymphomas like non-Hodgkins or Burkitt
lymphoma. However, until recently it was not possible to
efficiently transduce resting B lymphocytes with retro- or lentiviral
vectors making them unsusceptible for stable genetic manipula-
tions or gene therapy approaches [2]. Although lentiviral vectors
can transduce many types of non-proliferating cells, primary
human lymphocytes normally require stimulation with cytokines
or other factors and entry from G0 into G1b phase of cell cycle to
become transduced by these vectors. This holds true also for
lentiviral vectors pseudotyped with the glycoprotein of the
vesicular stomatitis virus (VSVG), which are basically the ‘‘gold
standard’’ to which all other lentiviral pseudotypes are compared.
Using different lentiviral pseudotypes it was observed that in
resting lymphocytes post-entry steps like completion of reverse
transcription, nuclear import and chromosomal integration of the
transgene do not occur [2–4].
However, recently we demonstrated that lentiviral vectors
pseudotyped with modified measles virus (MV) envelope proteins
hemagglutinin (H), responsible for receptor recognition, and fusion
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high efficiency [5–7]. The MV glycoproteins that are derived from
the NSe variant of the MV vaccine strain Edmonston B, are
truncated in their cytoplasmic tails to allow efficient incorporation
into the lentiviral envelope. Thereupon, the respective vector
particles (MV-LV) are able to mediate cell entry via the native MV
receptors human CD46 and signaling lymphocyte activation
molecule (SLAM). We found that interaction with both receptors
is essential to facilitate efficient transduction of resting lymphocytes
[8,9]. The recently identified third MV receptor nectin-4 does not
play a role in lymphocyte transduction as it is not expressed on this
cell type [10,11]. Importantly, MV-LV transduction does not lead
to lymphocyte activation as the cells remain in G0 state of cell
cycle [5,6].
MV glycoprotein pseudotyping can also be utilized to generate
targeted vectors that mediate specific entry into cell types of
choice. To confer specific target cell entry to the MV-LVs, we
abolished recognition of the MV receptors CD46 and SLAM by
mutating the truncated H protein at four residues in its
ectodomain, namely Y481A, R533A, S548L and F549S [12].
The desired receptor specificity is provided by displaying a single-
chain antibody (scFv) specific for the target receptor on the
mutated H protein (Hmut-scFv). Using this strategy, very different
cell surface molecules including type1-membrane glycoproteins
(CD105), pentaspan membrane glycoproteins (CD133), mem-
brane tetraspan calcium channels (CD20) as well as multi-subunit
ion-channels (glutamate receptors, GluR) can be used for cell
specific entry by these vectors. The respective targeting vectors
were not only able to selectively transduce receptor-positive cell
lines, but also the corresponding target receptor-positive primary
cells [7,13]. More importantly, remarkable target specificity was
observed in vivo, upon local or systemic injection into mice [13–
16].
Using CD20, a marker exclusively expressed on B lymphocytes,
as entry receptor, we found that the respective vector (CD20-LV)
is able to efficiently transduce unstimulated, resting primary
human B lymphocytes [7,17]. Since CD20 is especially expressed
on differentiated B cells but not on B cell precursors such as pro-B
and pre-B cells [18], here we generated a B lymphocyte targeted
vector utilizing CD19 for cell entry, which is a specific marker for
all B cell populations. As both, CD20 and CD19, are closely linked
to the B lymphocyte activation pathway [19–22], we investigated if
engagement and cross-linking of the receptors by the correspond-
ing targeted vector particles induces activating stimuli in resting B
lymphocytes, thereby rendering them susceptible for transduction.
We found that the CD19-targeted LV was highly specific for
CD19
+ cells in cell mixtures and stably transduced unstimulated
primary human B lymphocytes, albeit with a reduced efficiency
compared to CD20-LV. The activation marker CD71 was
substantially up-regulated on unstimulated B lymphocytes upon
transduction with CD20-LV. Furthermore, CD20-LV and
CD19ds-LV transduced B lymphocytes entered into the G1b cell
cycle phase.
Results
Generation of CD19 Targeting Vectors
For the generation of CD19 targeting vectors the genetic
information for two variants of the CD19-specific scFv (CD19-
scFv and CD19ds-scFv) [23,24] was fused to the Hmut reading
frame (Figure 1A). In pHmut-aCD19ds the CD19ds-scFv was
stabilized by a disulfide bond through introduction of cysteine
residues into the conserved framework regions [25]. For incorpo-
ration into lentiviral vector particles, which bud from the cell
surface, it is essential that the H constructs are expressed on the
surface of HEK-293T packaging cells. This was the case only for
the disulfide-stabilized Hmut-aCD19ds protein (Figure 1B).
Hence, this construct was used for all further experiments. After
expressing Hmut-aCD19ds protein together with all other compo-
nents of a lentiviral vector in HEK-293T cells, concentrated CD19
targeting vectors (CD19ds-LV) with a titer of 4.0610
6 transducing
units (t.u.)/ml could be generated (Figure 1C).
To evaluate the specificity of CD19ds-LV, we transduced a
series of mixtures of CD19
+ Raji cells and CD19
2 Molt 4.8 cells.
Besides by their CD19 levels, Molt 4.8 cells (CD8
+/CD19
2) can
also be distinguished from Raji cells (CD8
2/CD19
+) by CD8
expression. Since we observed that CD19 was strongly down-
regulated upon CD19ds-LV transduction (Figure 1D), we chose
CD8 as cell discriminating marker in this experiment. Different
ratios of Raji and Molt 4.8 cells were incubated with CD19ds-LV
or VSVG-LV control vectors, transferring the gene for the
enhanced green fluorescent protein (EGFP). 72 h later, the cells
were stained for CD8 and analyzed by FACS. CD19ds-LV vectors
selectively transduced the CD8
2 target cell population even when
it made up only 1% of the cell mixture, whereas non-target cells
remained untransduced (Figure 2). Normalized to the total
number of CD8
2/CD19
+ cells, CD19ds-LV transduced about 20–
30% of target cells in each cell mixture. In contrast, VSVG-LV did
not discriminate both cell lines (Figure 2). Hence, CD19ds-LV
demonstrated a high specificity for its target cell population.
Transduction of Unstimulated Primary Human B
Lymphocytes by CD20-LV and CD19ds-LV
We have previously shown that lentiviral vectors specific for the
B lymphocyte marker CD20 (CD20-LV) efficiently transduce
unstimulated primary human B lymphocytes [7]. Now, we
investigated if also CD19ds-LV vectors are able to transduce this
kind of cells. For this purpose, freshly isolated primary human B
lymphocytes were incubated with CD20-LV, CD19ds-LV,
VSVG-LV or MV-LV in complete absence of activating cytokines.
Forty-eight hours after incubation with CD20-LV on average
about 60% of unstimulated B lymphocytes of six different donors
were EGFP
+, whereas with VSVG-LV as a negative control no
EGFP
+ cells were detectable. MV-LV as a positive control
mediated EGFP expression in about 40% of unstimulated B cells
(Figure 3A). Also CD19ds-LV incubation led to EGFP
+ B
lymphocytes, albeit with a lower efficiency of about 20%
(Figure 3A). To assess the stability of gene transfer, we continued
to culture the transduced B lymphocytes of three different donors
on an MS-5 feeder cell layer in presence of rhIL-15 and rhIL-2 for
up to 10 days. After an initial decrease in EGFP
+ cells during the
first 4 days, which might be due to EGFP protein transfer, CD20-
LV transduced cells remained at a constant level of about 30%
EGFP expressing cells (Figure 3B,C). Upon CD19ds-LV
transduction, the percentage of EGFP
+ cells also slightly decreased
from day 2 to day 6, but then the level of EGFP expressing cells
was stable (Figure 3B,C). This data confirm the stable transgene
expression mediated by CD20-LV and CD19ds-LV transduction.
Moreover, during the whole observation period, the percentages of
EGFP
+ cells for CD19ds-LV transduced cells were significantly
higher than that of VSVG-LV transduced cells (Figure 3C).
Interestingly, CD19ds-LV transduction also strongly and tempo-
rarily down-regulated CD19 expression in primary human B
lymphocytes before the CD19 level was recovered six days after
transduction (Figure 3B). In summary, these data demonstrate
that in addition to CD20-LV, also CD19ds-LV transduced
unstimulated primary human B lymphocytes.
Targeted Vectors Induce Resting B Cell Activation
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Since CD20 as well as CD19 are closely linked to the B
lymphocyte activation pathway [19–22], we hypothesized that
the efficient transduction of resting B lymphocytes by CD20-LV
and CD19ds-LV was due to the induction of activating stimuli
in B lymphocytes upon vector engagement. Therefore, we
investigated if the activation markers CD69 and CD71 were up-
regulated on primary human B lymphocytes 48 h after
transduction with CD20-LV, CD19ds-LV or VSVG-LV. As
controls, untransduced B lymphocytes and cytokine stimulated B
lymphocytes were included. Although both CD19ds-LV and
CD20-LV show a tendency to up-regulate early (CD69) and
Figure 1. A stabilizing disulfide bond in aCD19ds-scFv is essential for generating CD19 targeting vectors. (A) Schematic drawing of the
cytoplasmic tail-truncated hemagglutinin envelope proteins displaying two aCD19 single-chain antibody (scFv) variants. In the mutated
hemagglutinin protein (Hmut) that is derived from the NSe variant of the measles virus (MV) vaccine strain Edmonston B, mutations in the MV receptor
recognition regions Y481A, R533A, S548L and F549S (ectodomain) [12] are indicated by asterisks. A glycine-serine linker ((G4S)3) is used as linker
region between Hmut and scFv. The aCD19-scFv and aCD19ds-scFv differ in the presence of a disulfide bond in aCD19ds-scFv. A histidine tag (H6) is
present at the scFv C-terminus. Both hemagglutinin proteins are truncated by 18 amino acids in their cytoplasmic tail (D18) to allow incorporation
into the lentiviral envelope. (B) Cell surface transport of the two different H variants was investigated upon transfection of plasmids pCG-Hmut-aCD19
(red line) and pCG-Hmut-aCD19ds (blue line) into HEK-293T cells. The empty expression plasmid pCG-1 (black line) was used as control. Forty-eight
hours after transfection, the cells were stained with a PE-conjugated anti-His antibody to detect cell surface expression of the H constructs by FACS
analysis. The respective histograms are shown. (C) To determine the titer of vector particles pseudotyped with Hmut-aCD19ds (CD19ds-LV), CD19
+ Raji
cells were transduced with serial dilutions of the concentrated vector particles. After 72 h, the percentage of EGFP
+ cells was determined by FACS
analysis. (D) To determine cell surface down-regulation of CD19 after CD19ds-LV transduction, CD19
+/CD20
+ Raji cells were transduced with CD19ds-
LV vectors at an MOI of 2 or remained untransduced. Forty-eight hours later, untransduced cells were stained with PE-conjugated anti-CD19 (left;
blue line) and PE-Cy5-conjugated anti-CD20 (right; blue line) antibody, or with the respective isotype controls (black lines). CD19ds-LV transduced
cells were stained with PE-conjugated anti-CD19 (left; red line) and PE-Cy5-conjugated anti-CD20 (right; red line) antibody. Then, CD19 and CD20
cell surface expression was analyzed by FACS.
doi:10.1371/journal.pone.0079047.g001
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regulated CD71 in a similar range as cytokine treatment
(Figure 4A). Also CD20-targeted virus like particles (CD20-
VLP) induced marker up-regulation to a similar extent as
CD20-LV. As expected, no difference between VSVG-LV
treated or untreated cells was observed (Figure 4A). Further-
more, some of the CD20-LV and CD19ds-LV transduced B
lymphocytes of four different donors progressed from the G0 to
the G1b phase of the cell cycle (Figure 4B and Table 1). For
example, 48 h after transduction 36.2% of CD20-LV and 9.6%
of CD19ds-LV transduced cells resided in G1b, whereas
untransduced cells remained completely in the G0 phase
(Figure 4B, Donor 1 in Table 1). Surprisingly, for two
donors CD20-LV transduced cells entered the cell cycle as
efficiently as B lymphocytes that were stimulated by cytokine
incubation (Table 1). In general, CD20-LV induced more
pronounced cell cycle progression and higher expression levels
of both activation markers than CD19ds-LV in all of the four
donors tested, although there was some variability between the
donors in the four independent cell cycle experiments (Table 1
and Figure 4A). As published previously [6], MV-LV vectors
did not induce cell cycle progression of resting B lymphocytes
(Figure 4B and Table 1), confirming the validity of our assay.
Notably, for the cell cycle experiments B lymphocytes isolated
instantly after blood donation using the BD Vacutainer
TM
CPT
TM system were used. This likely explains the lower B
lymphocyte transduction rates as compared to those seen with B
lymphocytes derived from buffy coats by centrifugation over
Histopaque-1077 (Table 1 and Figure 3A).
CD20-VLP and CD19ds-VLP do not Induce Measurable
Calcium Influx into Resting B Lymphocytes
It has been shown that certain types of CD20- and CD19-
specific monoclonal antibodies can cause calcium influx into B cell
lines [22,27]. Moreover, the sustained elevation of cytoplasmic free
calcium achieved through a combination of its release from
intracellular stores and influx of extracellular calcium via
membrane channels, is known to be required for B cell activation
[28]. Since the targeting domains of CD20-LV and CD19ds-LV
were monoclonal antibody derived and both of these two vectors
induced B cell activation, we next investigated if transduction of
resting B lymphocytes with CD20-LV and CD19ds-LV, respec-
tively, induced calcium influx. To avoid any interference with GFP
pseudotransduction in the calcium influx assay, we generated
VLPs instead of lentiviral vectors. CD20-VLP, CD19ds-VLP and
VSVG-VLP were equipped with the same envelope as the
corresponding lentiviral vector, but contained no transfer vector.
The same amounts of CD20-VLP, CD19ds-VLP and VSVG-VLP
(normalized by p24 titer) were added to eFluorH 514-labeled
resting primary human B lymphocytes. Calcium influx was
monitored by changes in the mean fluorescence intensity (MFI)
of the eFluorH 514-labled B lymphocytes that are directly related
to changes in the cytoplasmic calcium concentration. As a positive
control, B lymphocytes treated with 2 mM ionomycine were
included. While ionomycine induced significant calcium influx,
neither CD20-VLP, CD19ds-VLP nor VSVG-VLP induced any
detectable calcium influx (Figure 5). It thus appears that the
association of the displayed scFvs on the surface of CD20-LV and
CD19ds-LV with their receptors CD20 and CD19 does not induce
calcium influx into resting primary human B lymphocytes.
Figure 2. In presence of high numbers of non-target cells CD19ds-LV is specific for CD19
+ cells. CD19
2/CD8
+ Molt 4.8 cells were mixed in
the indicated ratios with CD19
+/CD8
2 Raji cells and transduced with CD19ds-LV or VSVG-LV vector particles at an MOI of 2 (refers to the total cell
number). After 72 h, the cells were stained for CD8 expression and the percentage of EGFP
+/CD8
2 cells was determined by FACS analysis. A gating
strategy was chosen in which the untransduced cells lay well within the EGFP-negative quadrants as shown in the upper left diagram.
doi:10.1371/journal.pone.0079047.g002
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Although lentiviral vectors can transduce many types of non-
proliferating cells, primary human lymphocytes normally require
stimulation and entry from G0 into G1b phase of the cell cycle to
become transduced by these vectors [2–4]. However, recently we
demonstrated that lentiviral vectors pseudotyped with modified
MV glycoproteins are able to transduce resting primary human
lymphocytes [5–7]. These vectors use either the natural MV
receptors CD46 and SLAM for cell entry (MV-LV) or the B
lymphocyte marker CD20 (CD20-LV). Here, we show in addition
that unstimulated B lymphocytes can be transduced via CD19,
another B lymphocyte specific molecule.
It has been shown that MV-LV vectors do not activate B
lymphocytes via the transduction process and that simultaneous
contact to both MV receptors CD46 and SLAM is crucial [6,8,9].
We proposed that transduction is facilitated by downstream
signaling from the MV receptors leading to actin cytoskeleton
remodeling [17]. Remodeling of the cortical actin cytoskeleton has
been shown to be a prerequisite for productive entry of HIV-1 into
resting lymphocytes [29]. These cytoskeleton rearrangements
might permit transport of vector particles and reverse transcribed
DNA to the nucleus, subsequently allowing gene integration
[9,17].
In addition, CD20-LV vectors, which use CD20 for cell entry
instead of CD46 and SLAM, also efficiently transduce resting B
lymphocytes. Since CD20 is involved in B lymphocyte activation
[19–22], we suggested that the transduction mechanism of CD20-
LV was different from that of MV-LV. Minimal activation of the
cells into G1b phase of cell cycle after engagement and cross-
linking of CD20 by CD20-LV vector particles might be the main
factor to allow transduction of resting B lymphocytes [17]. To
address this question, here we generated a novel B lymphocyte
specific lentiviral vector via targeting to CD19.
CD19 is an essential co-receptor on the surface of B
lymphocytes. It is part of a complex also containing CD21,
CD81 and leu13. However, there is increasing evidence that
CD19 may also be present and function alone, independently of
the CD21-CD19-CD81-leu13 complex [19]. It has been proposed
to function as an adaptor-like protein, mediating the recruitment
and activation of signaling molecules, like phosphatidylinositol 3-
kinase (PI3K), to B cell receptor (BCR) microclusters [30,31].
Furthermore, it might stabilize and amplify signaling within
individual BCR microclusters, thus enhancing BCR signaling and
facilitating B cell activation [19].
For CD20, there is increasing evidence that it has a function in
BCR induced calcium entry [21,22,32]. Intracellular signaling
events that follow BCR ligation, lead to rapid release of calcium
from the endoplasmic reticulum into the cytoplasm. Depletion of
the intracellular calcium stores then triggers a second phase of
calcium mobilization, characterized by sustained calcium entry
into the cell via plasma membrane-associated ‘‘store-operated’’
Figure 3. Stable transduction of unstimulated primary human B lymphocytes by CD20-LV and CD19ds-LV. (A) Freshly isolated primary
human B lymphocytes from six different donors were transduced with CD20-LV, CD19ds-LV or MV-LV at an MOI of 2, or VSVG-LV at an MOI of 100.
Forty-eight hours later, B lymphocytes were identified by their CD20 expression and the percentage of EGFP
+ cells in the CD20-gated cells was
determined by FACS analysis. Results are expressed as mean 6 SEM. *, ** and *** indicate P,0.05, P,0.01 and P,0.001 versus transduction with
CD20-LV, respectively. Data were analyzed by one-way ANOVA. (B–C) To verify stable integration of the egfp gene into the B lymphocyte genome,
freshly isolated primary human B lymphocytes (purity was ,99.8%) from three different donors were transduced with the indicated vectors.
Transduced cells were cultivated in presence of 10 ng/ml rhIL-15 and 10 ng/ml rhIL-2 for 10 days on MS-5 feeder cells. The percentage of CD19
+/
EGFP
+ cells in the CD20-gated cells was determined by FACS analysis at the indicated time points. (B) FACS blots of one representative experiment
are shown (at least 2000 B lymphocytes were gated for analysis). (C) Diagram showing a summary of all three independent experiments. Dark gray
column: CD20-LV; light gray column: CD19ds-LV; white column: VSVG-LV. Results are expressed as mean 6 SEM. * and ** indicate P,0.05 and P,0.01
for CD20-LV and CD19ds-LV versus VSVG-LV, respectively. Data were analyzed by Student’s t-test without adjustment of multiple comparisons.
doi:10.1371/journal.pone.0079047.g003
Targeted Vectors Induce Resting B Cell Activation
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the calcium response defines gene expression by calcium-sensitive
proteins [32]. It has been shown that BCR-activated calcium entry
was reduced after siRNA-mediated down-regulation of CD20 in a
human B cell line [33] and in CD20-deficient murine B cells [34].
This firmly points to a role for CD20 in BCR-activated SOCE,
although it is not yet clear whether CD20 is a channel, a
component of a channel, or if it regulates SOCE in some other
ways [21,32]. The binding of most mAbs to CD20 leads to its
redistribution into lipid rafts and generates transmembrane signals
that result in enhanced phosphorylation of CD20 and e.g.
induction of c-myc and B-myb oncogene expression. Furthermore,
it has been shown that the CD20 mAb 1F5 activates dense resting
(G0) tonsillar B cells and drives them into the G1 stage of the cell
Figure 4. CD20-LV and CD19ds-LV induce minimal activation of resting primary human B lymphocytes. (A) Freshly isolated primary
human B lymphocytes were left untransduced or were incubated with CD20-LV, CD19ds-LV or VSVG-LV at an MOI of 1.5–2 or with CD20-VLP at the
same HIV p24 value as CD20-LV. As positive control, B lymphocytes were activated with a cytokine cocktail consisting of 50 ng/ml IL-2, 300 ng/ml
CD40Ligand, 10 ng/ml IL-4 and 10 ng/ml IL-10. Forty-eight hours later, the cell surface expression of the activation markers CD69 and CD71 was
determined by FACS analysis using appropriate antibodies. Mean values of CD69
+ and CD71
+ cells, respectively, of four different donors and SEM are
shown. *, ***, and ****indicate P,0.05, P,0.001 and P,0.0001 versus untransduced cells, respectively. Data were analyzed by two-way ANOVA. (B)
Freshly isolated primary human B lymphocytes were transduced by CD20-LV (MOI 3), CD19ds-LV (MOI 3) or MV-LV (MOI 5) vectors or remained
untransduced. As positive control, B lymphocytes were activated with the same cytokine cocktail as described for (A). Forty-eight hours later, cell
cycle progression was monitored by simultaneously visualizing the RNA (pyronin-Y) and DNA (7-AAD) content of the B lymphocytes by FACS analysis.
The percentages of cells in G0, G1b or S/G2/M phase of the cell cycle are indicated. One representative experiment out of four independent
experiments is shown.
doi:10.1371/journal.pone.0079047.g004
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deliver an activation signal, it is insufficient on its own to initiate
entry into the S phase of the cell cycle and subsequent clonal
division [21,35].
In this study, unstimulated primary human B lymphocytes were
transduced by both CD20-LV and CD19ds-LV, the latter being
generally less efficient. Different reasons may account for this:
There is a 4-fold higher CD20 than CD19 expression level on the
surface of B lymphocytes [36] and we know from previous work
that target receptor density is crucial for efficient transduction
[15]. We also observed a strong down- regulation of CD19 surface
expression after transduction with CD19ds-LV, suggesting endo-
cytosis of CD19 after vector engagement. As the MV glycoproteins
are functional under neutral pH only, such particles will be unable
to escape from the endosomes and deliver the transferred gene to
the cell nucleus. Moreover, up-regulation of activation markers
was found to be more pronounced with CD20-LV than with
CD19ds-LV.
Our cell cycle analysis revealed that cells transduced by targeted
vectors entered the G1b phase, whereas untransduced cells or cells
transduced with MV-LV remained in G0. Especially, CD20-LV
transduced B lymphocytes entered the cell cycle comparably
efficient as cytokine stimulated cells in two out of four donors
tested. This is in line with the published results for 1F5 antibody
binding to CD20, which also induces cell cycle entry into G1, but
not entry into the S phase [21,35]. Thus, binding of CD20 by
aCD20-scFv displayed on the vector particle surface has the same
effect as antibody binding and it has been shown in numerous
publications that binding of antibodies to CD20 induces intracel-
lular signals [21,28]. Activation marker expression and cell cycle
entry was less pronounced for CD19ds-LV. Hence, binding of
CD19 by CD19ds-LV did not induce such strong activating
signals as CD20 binding. This is in line with many publications
describing the stimulation of B lymphocytes by CD20-specific
antibodies while such data are absent for CD19-specific antibodies
[21,35]. This may also well explain the lower transduction
Table 1. Cell cycle progression of resting primary human B lymphocytes after transduction with targeted vectors.
1.
Donor 1 Donor 2 Donor 3 Donor 4
G1b
cells [%]
GFP
+
cells [%] MOI
G1b
cells [%]
GFP
+
cells [%] MOI
G1b
cells [%]
GFP
+
cells [%] MOI
G1b
cells [%]
GFP
+
cells [%] MOI
CD20-LV 36.2 13.5 3 5.9 7.4 2 9.0 38.0 2 10.0 59.0 2
CD19ds-LV 9.6 4.9 3 5.1 25.8 2 2.8 16.0 2 n.d.
5 n.d. n.d.
MV-LV 1.1 11.8 5 2.0 46.4 5 0.9 35.0 2 0.0 40.0 10
untransduced
2 0.8 n.a.
4 n.a. 1.6 n.a. n.a. 0.8 n.a. n.a. 1.0 n.a. n.a.
untransduced
3 37.0 n.a. n.a. 14.6 n.a. n.a. 49.0 n.a. n.a. 10.0 n.a. n.a.
1Cells were analyzed 48 h after transduction.
2Unstimulated B lymphocytes were analyzed.
3B lymphocytes were stimulated for 48 h with a cytokine cocktail consisting of 50 ng/ml IL-2, 300 ng/ml CD40Ligand, 10 ng/ml IL-4 and 10 ng/ml IL-10.
4not applicable.
5not done.
doi:10.1371/journal.pone.0079047.t001
Figure 5. CD20-VLP and CD19ds-VLP do not induce calcium influx into unstimulated primary human B lymphocytes. Freshly isolated
primary human B lymphocytes were labeled with Calcium Sensor Dye eFluorH 514 and labeled cells were assessed by flow cytometry to establish a
baseline level of fluorescence. Then cells were removed, incubated with the indicated stimulants, and replaced immediately for further flow
cytometric analysis. The transient increase in intracellular calcium concentration was recorded by monitoring the change in MFI of the cells. To
determine the background auto-fluorescence of the cells, one sample was recorded without the addition of any stimulant after baseline monitoring
(mock). The gap in the histogram reflects the time-period when the tube containing the cells was removed from the instrument to add the
stimulants. The arrow indicates the time-point of addition of the stimulant. VLP: virus like particles; MFI: mean fluorescence intensity.
doi:10.1371/journal.pone.0079047.g005
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cytes as compared to CD20-LV.
Neither vector entry via CD20 nor via CD19 induced a
measurable Ca
2+ flux into B lymphocytes, whereas the ionomycine
positive control increased Ca
2+ flux about six fold above the
baseline level demonstrating that the sensitivity of our assay was
comparable to that of published flow cytometry based calcium
assays [37,38]. The absence of Ca
2+ influx after CD20-VLP and
CD19ds-VLP incubation was unexpected as CD19 as well as
CD20 are believed to play a role in BCR induced B lymphocyte
activation, which also involves Ca
2+ mobilization [20,21].
Especially CD20 seems to be involved in BCR mediated Ca
2+
entry [21,22,32]. It has been published that hyper-cross-linking of
bound CD20 mAb induces Ca
2+ influx into B cell lines [22].
However, not all CD20-specific antibodies induce calcium flux
after hyper-cross-linking. CD20 mAbs can be separated into two
distinct groups, whereby Type I mAbs are defined by their ability
to redistribute CD20 into detergent-insoluble plasma membrane
domains and to evoke complement-dependent cellular cytotoxicity
(CDC). Only Type I mAbs are able to induce calcium flux after
hyper-cross-linking with anti-Fc reagents [22].
As there are many scFvs presented on the vector particle
surface, it is likely, that CD20 molecules are cross-linked by bound
vector particles. However, this might not reflect the same situation
as hyper-cross-linked antibodies. Furthermore, it is not known if
the antibody clone B9E9 from which the presented CD20-scFv is
derived [39] belongs to Type I anti-CD20 antibodies. In general it
has been shown that binding of different CD20 antibodies leads to
different effects in B lymphocytes, probably because they bind
different epitopes on CD20 [21,35]. Binding by the displayed
aCD20-scFv seems to induce entry into G1b phase of cell cycle
without inducing detectable Ca
2+ influx. For CD19, although on
mouse B lymphocytes the CD19 engagement by dimeric anti-
CD19 mAb induces [Ca
2+]i responses, it is suggested that the
extent and valency of CD19 ligation determine the regulatory
function of CD19 on B cell activation and regulate the BCR-
induced [Ca
2+]i [40]. Possibly, the affinity of the aCD19ds-scFv or
the number of displayed aCD19ds-scFv on vector particles is not
sufficient to trigger calcium responses. The absence of any
detectable induction of Ca
2+ influx is in line with no increase in
CD19ds-LV mediated transduction, when we activated B
lymphocytes of three different donors with CD20-LV before
adding CD19ds-LV (data not shown). This reflects that although a
minimal B lymphocyte activation is critical for transduction,
signals induced by the interaction between the CD20-scFv and
CD20 are only active in cis but not in trans. Possibly, this
interaction opens an efficient vector entry route for particles
bound to CD20 but not for particles bound to other cell surface
receptors.
In conclusion, we demonstrated that CD20 and CD19 targeting
vectors specifically transduce unstimulated B lymphocytes, prob-
ably by inducing minimal activation of the cells into G1b phase of
cell cycle. Hence, retargeted vectors are not only able to mediate
specific gene transfer, but also modulate cell physiology.
Materials and Methods
Ethics Statement
The research has been approved by the Ethics Committee of
the University Hospital Frankfurt, Germany. Written informed
consent was obtained from each donor.
Plasmid Constructions
The plasmid pCG-Hmut-aCD20 encoding the truncated Hmut
protein displaying the aCD20-scFv was described previously [7].
Briefly, the aCD20-scFv was linked to the ectodomain of Hmut
protein via the factor Xa cleavage site (Xa). To generate the
plasmids pCG-Hmut-aCD19 and pCG-Hmut-aCD19ds, the re-
spective aCD19-scFv coding regions were PCR amplified with the
primers CD19-SfiI+ (TGCTTGGCCCAGCCGGCCATGGCG-
GACTACAAAGATATTG) and CD19-NotI-
(TATTCCTTTTGCGGCCGCCGAGGAGACGGT-
GACTGTG) using pSecTag2HygroC-CD19-4G7-EGFP [24] and
pSecTag2HygroC-Strep-CD19-4G7dsxCD16ds [23] as templates
encoding either the unstabilized or the disulfide bond stabilized
CD19-specific scFv which was subcloned from the hybridoma
clone 4G7 [23,24,41]. The PCR amplificates were digested with
SfiI and NotI and ligated into the SfiI and NotI digested pCG-
HmutL3 backbone encoding the cytoplasmic tail-truncated Hmut
protein with a (G4S)3 linker at its C-terminus [13].
The H protein plasmids were purified with the EndoFreeH
Plasmid Maxi Kit (Qiagen, Hilden, Germany), whereas all other
plasmids used for vector particle production were purified by the
PlasmidFactory GmbH & Co. KG, Bielefeld, Germany.
Cultivation of Cell Lines and Primary Human B
Lymphocytes
Culture of HEK-293T cells, Raji cells and Molt 4.8 cells has
been described previously [7,16]. Primary human B lymphocytes
were isolated from fresh human peripheral blood mononuclear
cells (PBMCs) using the Dynal B cell negative isolation kit
(Invitrogen, Karlsruhe, Germany) and cultivated in RPMI 1640
medium supplemented with 10% FCS, 1% glutamine, 0.5%
streptomycin/penicillin and 25 mmol/l HEPES [7]. The PBMCs
were either obtained from buffy coats by centrifugation over
Histopaque-1077 (Sigma-Aldrich, Taufkirchen, Germany) or for
the cell cycle analysis experiments from donors using the BD
Vacutainer
TM CPT
TM system with sodium citrate (BD, Heidel-
berg, Germany). Immediately after isolation, the purity of isolated
B lymphocytes was monitored by FACS analysis using PE-
conjugated anti-CD19 antibody (DakoCytomation, Glostrup,
Denmark) and PE-Cy5-conjugated anti-CD20 antibody (BD
Pharmingen, Heidelberg, Germany). Unstimulated B lymphocytes
were confirmed to be negative for the activation marker CD69
using the PE-conjugated anti-CD69 antibody (BioLegend, San
Diego, USA).
Vector Particle Production and Titration
Lentiviral vector particles were produced by polyethyleneimine
(PEI) based transfection of HEK-293T cells as described
previously [42]. Briefly, 2610
7 cells were seeded 24 h before
transfection into a T175 flask. On the day of transfection, medium
was replaced with 10 ml of DMEM supplemented with 15% FCS
and 2 mM L-glutamine. For targeting vectors, 1.35 mg of pCG-
Hmut-aCD20 [7] or pCG-Hmut-aCD19ds, 4 mg of pCG-FcD30
[7], 14.4 mg of packaging plasmid pCMVDR8.9 [43] and 15.2 mg
of transfer vector plasmid pSEW [44], encoding EGFP, were
mixed with 2.3 ml DMEM without supplements. For MV-LV
vectors, 1.35 mg of pCG-HcD18 [7] and 9.4 mg of pCG-FcD30
together with 9.1 mg pCMVDR8.9 and 15.2 mg pSEW were
applied. In parallel, 140 ml of 18 mM PEI and 2.2 ml DMEM
without supplements were mixed. The PEI mixture and the DNA
mixture were combined, vortexed and incubated for 20 min at
room temperature (25uC), before the transfection mixture was
added to the cells. Twenty-four hours later, medium was
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FCS and 2 mM L-glutamine. The cell supernatant containing the
pseudotyped vector particles was filtered 24 h later (0.45-mm
filter). The vector particles were concentrated 270-fold by
ultracentrifugation over a 20% (wt/vol) sucrose cushion
(100,000 g for 3 h at 4uC). Vector particles pseudotyped with
VSVG were produced by co-transfection of 6.13 mg pMD.G2
(kindly provided by Didier Trono, Tronolab, Lausanne, Switzer-
land), 11.4 mg pCMVDR8.9 and 17.5 mg pSEW. Targeting
vectors and control vectors were titrated on Raji cells. EGFP
+
cells were determined by FACS analysis and vector stock titers
were calculated as described previously [7,13]. Briefly, cells were
transduced by at least five serial dilutions of vector particles. Titer
calculation was based on those samples showing a linear
correlation of EGFP expression with the dilution factor. We
observed correlations in the range from four-fold up to nine-fold
increase in transduction efficiency by a ten-fold increase in
supernatant volume for all lentiviral vectors.
Transduction of Cells
For transduction of cell lines, 1610
5 cells per well of a 48 well
plate were incubated with the indicated amount of vector particles
and 4 mg/ml protamine sulfate (Sigma-Aldrich, Munich, Ger-
many) in a final volume of 250 ml for 3 h at 37uC in a cell culture
incubator. Then, 500 ml fresh medium was added. After 72 h,
transgene expression was determined by FACS analysis. To study
specific gene transfer, Raji and Molt 4.8 cells were co-cultivated at
the indicated ratios and transduced by CD19ds-LV or VSVG-LV
vectors at an MOI of 2 calculated based on total cell numbers. For
transduction of freshly isolated B lymphocytes, the indicated vector
particles and 4 mg/ml protamine-sulfate were added together with
3610
4 B lymphocytes in a final volume of 100 ml into a well of a
96 well plate and were centrifugated for 1 h at 4806g, 32uC.
Then, 100 ml fresh medium was added and the cells were cultured
for 48 h at 37uC in a cell culture incubator, before the percentage
of EGFP
+ B lymphocytes was determined by FACS analysis. For
long-term culture of transduced unstimulated B lymphocytes, the
cells were transferred onto MS-5 feeder cells [45] in RPMI
supplemented with 10% FCS, 10 ng/ml rhIL-15 (Roche,
Mannheim, Germany) and 10 ng/ml rhIL-2 (Roche, Mannheim,
Germany) and passed onto a new MS-5 cell monolayer every 4
days.
Flow Cytometry
Flow cytometry and identification of B lymphocytes was
performed as described previously [13]. For surface expression
experiments, 2610
5 HEK-293T cells were transfected in a 6 well
plate with pCG-Hmut-aCD19, pCG-Hmut-aCD19ds and pCG-1
expression plasmids, respectively, by Lipofectamine transfection
reagent (Invitrogen, Darmstadt, Germany) according to the
manufacturer’s instructions. After 48 h, cells were detached by
PBS-trypsin incubation and washed once in FACS washing buffer
(PBS, 1% FCS, 0.1% NaN3) before they were incubated for
20 min at 4uC in the dark with a PE-conjugated anti-His antibody
(MiltenyiBiotec, Bergisch Gladbach, Germany) to detect His-
tagged Hmut-aCD19 and Hmut-aCD19ds proteins. After antibody
incubation, the cells were washed twice in FACS washing buffer
and were then fixed in 100 ml PBS/1% paraformaldehyde, before
they were applied to FACS analysis. For detection of CD8
+ Molt
4.8 cells in cell mixtures, an APC-conjugated anti-CD8 antibody
(BD Pharmingen, Heidelberg, Germany) was used. For detection
of CD19
+/CD20
+ B lymphocytes, a PE-conjugated anti-CD19
antibody (DakoCytomation, Glostrup, Denmark) and a PE-Cy5-
conjugated anti-CD20 antibody (BD Pharmingen, Heidelberg,
Germany) was applied. To identify B lymphocyte activation, PE-
conjugated anti-CD69 antibody (BioLegend, San Diego, USA)
and PE-conjugated anti-CD71 antibody (BD Pharmingen, Heidel-
berg, Germany) was used. The respective isotype control
antibodies were applied as controls. Data were obtained with the
LSR II FACS machine (Becton Dickinson, Heidelberg, Germany)
and analyzed with the FACSDiva software (Becton Dickinson,
Heidelberg, Germany) or the FCS express software (De novo
Software, Los Angeles, CA, USA).
Cell Cycle Analysis
Cell cycle analysis was performed by staining the DNA and
RNA content of B lymphocytes with 7-Aminoactinomycin D (7-
AAD; Sigma-Aldrich, Munich, Germany) and pyronin Y (Sigma-
Aldrich, Munich, Germany), respectively. 1610
5 cells were
washed with 4 ml PBS before they were incubated for 30 min at
room temperature (25uC) in 300 ml NASS buffer (0.1 M
phosphate-citrate, 5 mM EDTA, 0.5% w/v BSA, 0.15 M NaCl,
0.03% Saponine, pH 6.0 in H2O) supplemented with 0.02 mg/ml
7-AAD. After 5 min incubation on ice, 0.007 mg/ml pyronin Y
was added. The cells were incubated for additional 10 min on ice,
before they were immediately analyzed on a LSR II FACS
machine.
Calcium Assay
Freshly isolated primary human B lymphocytes were incubated
in serum-free, calcium-free PBS containing 5 mM Calcium Sensor
Dye eFluorH 514 (eBioscience, Frankfurt, Germany) for 30
minutes at 37uC. Cells were then washed twice with PBS and
resuspended at 5610
5 cells/mL in HBSS (Hank’s Balanced Salt
Solution) (Invitrogen, Darmstadt, Germany) supplemented with
20 mM HEPES (N-2-hydroxyethylpiperazine-N9-2-ethanesulfo-
nic acid) (Invitrogen, Darmstadt, Germany). The viability of cells
was higher than 95% as determined by trypan blue dye exclusion.
The cells were kept at room temperature until they were analyzed
by FACS using a LSR II flow cytometer (Becton Dickinson,
Heidelberg, Germany). For each sample, a 60 s baseline
monitoring was performed. Then sample aspiration was briefly
paused and stimulant (CD20-VLP, CD19ds-VLP, VSVG-VLP or
ionomycine) was quickly added before the acquisition was
continued at rates of approximately 300 events/second for a total
of 250 s. The changes in calcium concentration were analyzed by
the change in mean fluorescent intensity (MFI) of eFluorH 514-
labeled cells over the time. The data acquired were analyzed using
FCS Express software (De novo Software, Los Angeles, CA, USA).
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